Prolonged survival in a nasopharyngeal carcinoma patient with multiple metastases: a case report and review of the literature

Jpn J Clin Oncol. 1997 Oct;27(5):336-9. doi: 10.1093/jjco/27.5.336.

Abstract

Nasopharyngeal carcinoma is a common cancer in South East Asia. In the early stages, radiotherapy alone may achieve sustained control, but once metastasis occurs, it becomes an incurable disease with limited survival time. We report a case of nasopharyngeal carcinoma, initial stage T4N0M0, diagnosed in 1985 in a patient aged 36 years who received 70 Gy radiotherapy to the head and neck region. In 1988, relapse occurred with multiple lung metastases. The patient received many chemotherapy regimens with a very good response, including near complete remission with the first treatment regimen of cisplatin, 5-fluorouracil and leucovorin for lung metastases, and with the fifth chemotherapy regimen of ifosfamide as a single agent. After ifosfamide treatment, there was residual fibrotic change in the lung and complete disappearance, lasting for almost a year, of the liver and bone lesions. The patient eventually died in July 1995 due to progressive disease. Prolonged survival after mainly thoracic metastasis is possible in patients with nasopharyngeal carcinoma, especially if the tumor is chemo-responsive.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Agents, Alkylating / administration & dosage*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bone Neoplasms / secondary
  • Cisplatin / administration & dosage
  • Combined Modality Therapy
  • Drug Administration Schedule
  • Fluorouracil / administration & dosage
  • Humans
  • Ifosfamide / administration & dosage*
  • Leucovorin / administration & dosage
  • Liver Neoplasms / secondary
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / secondary*
  • Male
  • Nasopharyngeal Neoplasms / pathology
  • Nasopharyngeal Neoplasms / radiotherapy*
  • Survivors

Substances

  • Antineoplastic Agents, Alkylating
  • Cisplatin
  • Leucovorin
  • Fluorouracil
  • Ifosfamide

Supplementary concepts

  • PFL protocol